| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8518919 | MYLAN SPECIALITY LP | Compositions comprising azelastine and methods of use thereof |
Nov, 2025
(1 year, 6 months from now) | |
| US9919050 | MYLAN SPECIALITY LP | Compositions comprising azelastine |
Nov, 2025
(1 year, 6 months from now) | |
| US8071073 | MYLAN SPECIALITY LP | Compositions comprising azelastine and methods of use thereof |
Jun, 2028
(4 years from now) | |
Astepro is owned by Mylan Speciality Lp.
Astepro contains Azelastine Hydrochloride.
Astepro has a total of 3 drug patents out of which 0 drug patents have expired.
Astepro was authorised for market use on 15 October, 2008.
Astepro is available in spray, metered;nasal dosage forms.
Astepro can be used as treatment of allergic rhinitis, including seasonal and perennial allergic rhinitis.
The generics of Astepro are possible to be released after 04 June, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 15, 2011 |
| New Patient Population(NPP) | Aug 30, 2016 |
| M(M-129) | Aug 30, 2016 |
Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 October, 2008
Treatment: Treatment of allergic rhinitis, including seasonal and perennial allergic rhinitis
Dosage: SPRAY, METERED;NASAL
ASTEPRO family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8518919 | MEDA PHARMS | Compositions comprising azelastine and methods of use thereof |
Nov, 2025
(1 year, 6 months from now) | |
| US8071073 | MEDA PHARMS | Compositions comprising azelastine and methods of use thereof |
Jun, 2028
(4 years from now) | |
Astepro is owned by Meda Pharms.
Astepro contains Azelastine Hydrochloride.
Astepro has a total of 2 drug patents out of which 0 drug patents have expired.
Astepro was authorised for market use on 31 August, 2009.
Astepro is available in spray, metered;nasal dosage forms.
Astepro can be used as treatment of allergic rhinitis, including seasonal and perennial allergic rhinitis.
The generics of Astepro are possible to be released after 04 June, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 31, 2012 |
Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 31 August, 2009
Treatment: Treatment of allergic rhinitis, including seasonal and perennial allergic rhinitis
Dosage: SPRAY, METERED;NASAL
ASTEPRO family patents